Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis

Clinical Interventions in Aging

Volumn 3, Issue 4, 2008, Pages 719-728

  Campbell, Noll ^a   Ayub, Amir ^b   Boustani, Malaz A ^b   Fox, Chris ^c   Farlow, Martin ^d   Maidment, Ian ^c   Howard, Robert ^e  

^a WISHARD HEALTH SERVICES   (United States)

^b INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^c UNIVERSITY OF KENT   (United Kingdom)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Behavioral and psychological symptoms; Cholinesterase inhibitors; Dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; BEHAVIOR; CHOLINESTERASE INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60749130048     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. AD2000 Collaborative Group. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet, 363:2105-14.
2. Ballard CG, Margallo-Lana M, Fossey J, et al.200l. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry, 62:631-6.
3. Boustani M, Peterson B, Hanson L, et al. 2002. Screening for Dementia. Systematic Evidence Review [online]. Accessed on Aug 29, 2008. URL: http://www.ahrq.gov/clinic/uspstfix. Rockville, MD: Agency for Healthcare Research and Quality.
4. Brodaty H, Draper B, Saab D, et al. 2001. Psychosis, depression, and behavioral disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry, 16:504-12.
5. Chung JA, Cummings JL. 2000. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clinics, 18:829-46.
6. Cohen-Mansfield J. 1995. Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. J Geriatr Psychiatry Neurol, 8:52-60.
7. Colerick EJ, George LK. 1986. Predictors of institutionalization among caregivers of patients with Alzheimer's disease. J Am Geriatr Soc, 34:492-8.
8. Cummings JL, Donohue JA, Brooks RL. 2000. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry, 8:134-40.
9. Cummings JL, Kaufer D. 1996. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology, 47:876-83.
10. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44:2308-14.
11. Cummings JL, Nadel A, Masterman D, et al. 2001. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.J Geriatr Psychiatry Neurol, 14:101-8.
12. Cummings JL. 2000a. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry, 157:4-15.
13. Cummings JL. 2000b. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging, 21:845-61.
14. Devanand DP, Jacobs DM, Tang MX, et al. 1997. The course of psychopathological features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry, 54:257-63.
15. Doody RS, Stevens JC, Beck C, et al. 2001. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56:1154-66.
16. Erkinjuntti T, Kurz A, Gauthier S, et al. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet, 359:1283-90.
17. Feldman H, Gauthier S, Hecker J, et al. 2001. A 24-week, randomized, double-blind study of Donepezil in moderate to severe Alzheimer's disease. Neurology, 57:613-20.
18. Finkel SI, Burns A, Cohen GD. 2000. Overview. Int Psychogeriatr, 12(Suppl):13-8.
19. Gauthier S, Feldman H, Hecker J, et al. 2002. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin, 18:347-54.
20. Green CR, Mann DB, Mohs RC, et al. 1999. The impact of behavioral impairment on functional ability in Alzheimer's disease. Int J Geriatr Psychiatry, 14:307-16.
21. Hamel M, Gold DP, Andres D, et al. 1990. Predictors and consequences of aggressive behavior by community-based dementia patients. Gerontologist, 30:206-11.
22. Haupt M, Kurz A, Janner M. 2000. A 2-year follow-up of behavioral and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord, 11:147-52.
23. Haupt M, Kurz A. 1993. Predictors of nursing home placement in patients with Alzheimer's disease. Int J Geriatr Psychiatr, 8:741-7.
24. Holmes C, Wilkinson D, Dean C, et al. 2004. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurologyi, 63:214-9.
25. Howard RJ, Juszczak E, Ballard CG, et al. 2007. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med, 357:382-92.
26. Iverson GL, Hopp GA, DeWolfe K, et al. 2002. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. Int J Geriatr Psychiatry, 17:438-43.
27. Kaufer DI, Cummings JL, Christine D, et al. 1998. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc, 46:210-5.
28. Kinney JM, Stephens MA. 1989. Caregiving Hassle Scale: assessment the daily hassles of caring for a family member with dementia. Gerontologist, 29:328-32.
29. Levy ML, Cummings JL, Fairbanks LA, et al. 1996. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry, 153:1438-43.
30. Lyketsos CG, Lopez O, Jones B, et al. 2002. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA, 288:1475-83.
31. Lyketsos CG, Steinberg M, Tschanz JT, et al. 2000. Mental and behavioral disturbances in dementia: findings from the Cache county study on memory in aging. Am J Psychiatry, 157:708-14.
32. Maslach C, Jackson SE. 1981. The measurement of experienced burnout. J Occup Behav, 2:99-113.
33. McKeith I, Del Ser T, Spano P, et al. 2002. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet, 356:2031-6.
34. Morris PK, Rovner BW, German PS. 1996. Factors contributing to nursing home admission because of disruptive behavior. Int J Geriatr Psychiatry, 11:243-9.
35. Mulsant BH, Mazumdar S, Pollock BG, et al. 1997. Methodological issues in characterizing treatment response in demented patients with behavioral disturbances. Int J Geriatr Psychiatry, 12:537-47.
36. Nunez M, Jakab G, Jakobsen S, et al. 2003. Donepezil-treated Alzheimer's disease patients initially rated as showing 'no apparent clinical benefit' demonstrate significant benefits when therapy is continued [abstract]. AGS Annual Meeting, 2003. S99.
37. O'Donnell BF, Drachman DA, Barnes HJ, et al. 1992. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol, 5:45-52.
38. Rockwood K, Mintzer J, Truyen L, et al. 2001. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. Neurol Neurosurg Psychiatry, 71:589-95.
39. Schneider LS, Tariot PN, Lyketsos CG, et al. 2001. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatr, 9:346-60.
40. Steele C, Rovner B, Chase GA, et al. 1990. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry, 147:1049-51.
41. Steinberg M, Sheppard JM, Tschanz J, et al. 2003. The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci, 15:340-5.
42. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine in the treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry, 57:968-76.
43. Swearer JM. 1994. Behavioral disturbances in dementia. In: Morris JC (ed). Handbook of Dementing Illnesses. New York: Marcel Dekker, pp. 499-527.
44. Tariot PN, Blazina L. 1994. The psychopathology of dementia. In: Morris JC (ed). Handbook of Dementing Illnesses. New York: Marcel Dekker, pp. 461-75.
45. Tariot PN, Cummings JL, Katz IR, et al. 2001. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc, 49:1590-9.
46. Tariot PN, Solomon PR, Morris JC, et al. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 54:2269-76.
47. Teresi JA, Weiner AS. 1993. Respite care in the nursing home: predictors of length of stay. In: Tepper LM, Toner JA (eds). Respite Care: Programs, Problems and Solutions. Philadelphia: Charles Press, pp. 183-200.
48. Trinh NH, Hoblyn J, Mohanty S, et al. 2003. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's Disease: A meta-analysis. JAMA, 289:210-6.
49. Wilcock G, Black SE, Hendrix SB et al. 2008. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomized phase 11 trial. Lancet Neurol, 7:483-93.
50. Winblad B, Cummings J, Andreasen N, et al. 2007. A six month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease- Rivastigmine patch vs capsule. Int J Geriatr Psychiatry, 22:456-67.
51. Winblad B, Engedal K, Soininen H, et al. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57:489-95.
52. Winblad B, Kilander L, Eriksson S, et al. 2006. Donepezil in patients with severe Alzheimer's disease: double blind, parallel-group, placebo-controlled study. Lancet, 367:1057-65.
53. Wood S, Cummings JL, Hsu MA, et al. 2000. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry, 8:75-83.